Table 1.
Current guidelines
| Main society/organization | Focus | Type | Year |
|---|---|---|---|
| American College of Obstetricians and Gynecologists | Management of menopausal symptoms [16] | Practice bulletin | 2014; reaffirmed 2018 |
| American College of Obstetricians and Gynecologists | Management of gynecologic issues in women with breast cancer [17] | Practice bulletin | 2012; reaffirmed 2016 |
| American Society of Clinical Oncologya | Sexual problems in people with cancer [18] | Clinical practice guideline | 2017 |
| Endocrine Societyb | Treatment of symptoms of menopause [19] | Clinical practice guideline | 2015 |
| Endocrine Societyc | Androgen therapy in women [20] | Clinical practice guideline | 2014 |
| International Menopause Society | Women’s mid-life health and menopause hormone therapy [21] | Recommendations | 2016 |
| International Society for the Study of Women’s Sexual Health/North American Menopause Society | The role of androgens in the treatment of GSM [22] | Consensus panel review | 2018 |
| National Comprehensive Cancer Network | Principles of menopause management in female survivors [23] | Clinical practice guideline | 2019 |
| North American Menopause Society | Management of symptomatic VVA [24] | Position statement | 2013 |
| North American Menopause Society | Non-hormonal management of VMS [25] | Position statement | 2015 |
| North American Menopause Societyd | Hormone therapy position statement [15] | Position statement | 2017 |
| North American Menopause Society/International Society for the Study of Women’s Sexual Health | Management of GSM in women with or at high risk for breast cancer [26] | Consensus recommendation | 2018 |
GSM genitourinary syndrome of menopause, VMS vasomotor symptoms, VVA vulvovaginal atrophy
aAdapted from Cancer Care Ontario recommendations. Available from: https://www.cancercareontario.ca/en/content/interventions-address-sexual-problems-people-cancer
bCo-sponsored by The Australasian Menopause Society, British Menopause Society, European Menopause and Andropause Society, European Society of Endocrinology, and the International Menopause Society
cEndorsed by the American Society for Reproductive Medicine, American Congress of Obstetricians and Gynecologists, European Society of Endocrinology, and the International Menopause Society
dEndorsed by the Academy of Women’s Health, American Association of Clinical Endocrinologists, American Association of Nurse Practitioners, American Medical Women’s Association, American Society for Reproductive Medicine, Asociación Mexicana para el Estudio del Climaterio, Association of Reproductive Health Professionals, Australasian Menopause Society, Chinese Menopause Society, Colegio Mexicano de Especialistas en Ginecologia y Obstetricia, Czech Menopause and Andropause Society, Dominican Menopause Society, European Menopause and Andropause Society, German Menopause Society, Groupe d’études de la ménopause et du vieillissement Hormonal, HealthyWomen, Indian Menopause Society, International Menopause Society, International Osteoporosis Foundation, International Society for the Study of Women’s Sexual Health, Israeli Menopause Society, Japan Society of Menopause and Women’s Health, Korean Society of Menopause, Menopause Research Society of Singapore, National Association of Nurse Practitioners in Women’s Health, SOBRAC and FEBRASGO, SIGMA Canadian Menopause Society, Società Italiana della Menopausa, Society of Obstetricians and Gynaecologists of Canada, South African Menopause Society, Taiwanese Menopause Society, and the Thai Menopause Society. The American College of Obstetricians and Gynecologists supports the value of this clinical document as an educational tool, June 2017. The British Menopause Society supports this Position Statement